Hated Pharma Cash Machines: GARP in Big Drugmakers

While the tape obsesses over an AI revenue miss, big pharma is the classic Lynch setup: hated, cheap, and throwing off cash while pipelines quietly deliver. Several of these names trade at single-digit to mid-teens P/Es against double-digit growth drivers (oncology, immunology, GLP-1s), giving PEGs at or below 1. Policy tailwinds for transatlantic biotech and a durable two-player obesity market add a floor under earnings. This is where I'd rather be a buyer than chasing the AI complex after an OpenAI revenue disappointment. Catalysts: - 2026-10-08 CEPA urges transatlantic biotech partnership versus China, citing GLP-1s and biomanufacturing (https://cepa.org/comprehensive-reports/forging-a-transatlantic-biotechnology-partnership-to-confront-the-china-conflict/) - 2026-09-25 Novo resets obesity strategy as Lilly extends GLP-1 lead (https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html) Launch basket (equal weight): MRK, ABBV, LLY, AMGN, MRNA, NVO, GILD, BMY, PFE, VRTX Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.